Core B: Testing and Biorepository

核心B摘要 核心B（测试和生物储存库）提供的服务对本区域的所有项目和核心至关重要。 血清学测试，以改善COVID-19（STOP-COVID）中心的结果。血清学和病毒数据来自 三个项目将利用纵向收集的核心B来了解 第一反应者及其家庭接触者的患病率、传播和保护， 仍处于SARS-CoV-2暴露高风险的个人。核心B的主要目标是： 将五年纵向研究期间收集的血清和细胞样本存档（目标1），（ii）进行病毒 对鼻咽拭子进行检测（目标2），（iii）生成关于水平、同种型、特异性 所有项目（目标3）的抗体和中和活性，以及（iv）解释所有STOP-COVID数据 组成部分，继续专注于产生新的，可测试的关于COVID传播的假设， 战略保护。核心B的关键属性是，我们有（i）内部，FDA批准的病毒检测， (ii)一组经验证的抗体测定，其测量不同的抗原特异性和IG同种型，（iii）测定 用于通过血清抗体中和病毒，以及（iv）现有的COVID生物储存库基础设施。核心B 人员已经开发或验证了这些测定中的每一种。重要的是，核心B还确保了 来自俄勒冈州立大学的资金，以支持我们提出的大部分测试。核心A、B和C将通过接口连接， 数据/元数据的存储、安全性和深入分析。项目1、3和核心A-C将协同作用， 将我们小组生成的测试数据传达给SeroNet，考虑其直接影响和 我们对COVID病因学、发病机制和免疫力不断发展的认识。核心B将与 项目3是关于如何将这些数据传达给STOP-COVID参与者的方法，重点是对这些数据的解释， 目前的影响，以及它们将如何指导未来的缓解做法。总之，核心B将促进 收集、分析和解释第一层血清学和病毒qRT-PCR数据，这将产生新的 关于COVID传播和保护的假设（项目1-2，核心A和C）。因此，综合 核心项目B提供的服务和分析将在概念上推进所有项目， 所有项目和核心的下游研究，并最终应确定新的方法来阻止COVID 或抑制其传播。

CORE B SUMMARY The services provided by Core B (Testing and Biorepository) will be essential for all Projects and Cores in the Serological Testing to Improve Outcomes from COVID-19 (STOP-COVID) Center. Serology and viral data from Core B, collected longitudinally, will be leveraged by the three Projects to understand determinants of prevalence, transmission, and protection in first responders and their household contacts, a cohort of individuals who remain at high risk for exposure to SARS-CoV-2. The major goals for Core B will be to: (i) archive serum and cell samples collected during the five-year longitudinal study (Aim 1), (ii) perform virus testing on nasopharyngeal swabs (Aim 2), (iii) generate first-tier serology data on levels, isotypes, specificities, and neutralization activities of antibodies for all Projects (Aim 3), and (iv) interpret data with all STOP-COVID components, keeping a focus on producing new, testable hypotheses about COVID transmission and strategies for protection. Key attributes of Core B are that we have (i) in-house, FDA-approved testing for virus, (ii) a battery of validated antibody assays that measure distinct antigen specificities and Ig isotypes, (iii) assays for virus neutralization by serum antibodies, and (iv) an existing COVID biorepository infrastructure. Core B personnel have either developed or validated each of these assays. Importantly, Core B has also secured funding from OSU to support the bulk of our proposed testing. Cores A, B, and C will interface for storage, security, and deep analysis of data/metadata. Projects 1, 3, and Cores A-C will synergize to communicate testing data generated by our group to SeroNet, with regard to their immediate impact and on our evolving knowledge about COVID etiology, pathogenesis, and immunity. Core B will work closely with Project 3 on methods to communicate these data to STOP-COVID participants, focusing on their interpretation, current impact, and how they will guide future practices for mitigation. In summary, Core B will facilitate the collection, analysis, and interpretation of first-tier serological and viral qRT-PCR data, which will generate new hypotheses about COVID transmission and protection (Projects 1-2, Cores A and C). Thus, the integrative services and analyses provided by Core B will advance all Projects conceptually, will facilitate prioritization of downstream studies by all Projects and Cores and, ultimately, should identify new approaches to stop COVID or inhibit its transmission.